Ginkgo Bioworks Holdings (DNA) - Net Assets
Based on the latest financial reports, Ginkgo Bioworks Holdings (DNA) has net assets worth $508.59 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.12 Billion) and total liabilities ($611.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DNA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $508.59 Million |
| % of Total Assets | 45.42% |
| Annual Growth Rate | 0.22% |
| 5-Year Change | -67.55% |
| 10-Year Change | N/A |
| Growth Volatility | 95.66 |
Ginkgo Bioworks Holdings - Net Assets Trend (2019–2025)
This chart illustrates how Ginkgo Bioworks Holdings's net assets have evolved over time, based on quarterly financial data. Also explore Ginkgo Bioworks Holdings total assets for the complete picture of this company's asset base.
Annual Net Assets for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual net assets of Ginkgo Bioworks Holdings from 2019 to 2025. For live valuation and market cap data, see DNA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $508.59 Million | -28.97% |
| 2024-12-31 | $716.06 Million | -34.73% |
| 2023-12-31 | $1.10 Billion | -36.81% |
| 2022-12-31 | $1.74 Billion | +10.78% |
| 2021-12-31 | $1.57 Billion | +233.45% |
| 2020-12-31 | $470.05 Million | -6.34% |
| 2019-12-31 | $501.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ginkgo Bioworks Holdings's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 580905100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $1.85 Million | 0.36% |
| Other Components | $6.66 Billion | 1308.92% |
| Total Equity | $508.59 Million | 100.00% |
Ginkgo Bioworks Holdings Competitors by Market Cap
The table below lists competitors of Ginkgo Bioworks Holdings ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dhipaya Group Holdings PCL
BK:TIPH-R
|
$396.40 Million |
|
AfreecaTV Co. Ltd
KQ:067160
|
$396.49 Million |
|
HD Renewable Energy Co. Ltd.
TW:6873
|
$396.52 Million |
|
Niagen Bioscience, Inc.
NASDAQ:NAGE
|
$396.64 Million |
|
Somalogic Inc
NASDAQ:SLGC
|
$396.23 Million |
|
Tubacex S.A
MC:TUB
|
$396.10 Million |
|
Neumora Therapeutics, Inc.
NASDAQ:NMRA
|
$395.96 Million |
|
Mangalore Chemicals & Fertilizers Limited
NSE:MANGCHEFER
|
$395.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ginkgo Bioworks Holdings's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 716,058,000 to 508,590,000, a change of -207,468,000 (-29.0%).
- Net loss of 312,763,000 reduced equity.
- New share issuances of 19,469,000 increased equity.
- Other comprehensive income increased equity by 3,657,000.
- Other factors increased equity by 82,169,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-312.76 Million | -61.5% |
| Share Issuances | $19.47 Million | +3.83% |
| Other Comprehensive Income | $3.66 Million | +0.72% |
| Other Changes | $82.17 Million | +16.16% |
| Total Change | $- | -28.97% |
Book Value vs Market Value Analysis
This analysis compares Ginkgo Bioworks Holdings's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.59x to 1.10x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $17.16 | $10.08 | x |
| 2020-12-31 | $14.48 | $10.08 | x |
| 2021-12-31 | $44.26 | $10.08 | x |
| 2022-12-31 | $41.34 | $10.08 | x |
| 2023-12-31 | $22.57 | $10.08 | x |
| 2024-12-31 | $13.80 | $10.08 | x |
| 2025-12-31 | $9.17 | $10.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ginkgo Bioworks Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -183.81%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 2.20x
- Recent ROE (-61.50%) is above the historical average (-73.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -24.20% | -220.23% | 0.08x | 1.41x | $-168.63 Million |
| 2020 | -27.44% | -165.16% | 0.11x | 1.46x | $-172.75 Million |
| 2021 | -121.57% | -583.12% | 0.15x | 1.38x | $-1.98 Billion |
| 2022 | -121.23% | -440.63% | 0.19x | 1.46x | $-2.28 Billion |
| 2023 | -81.38% | -355.08% | 0.15x | 1.52x | $-1.00 Billion |
| 2024 | -76.39% | -240.94% | 0.16x | 1.92x | $-618.63 Million |
| 2025 | -61.50% | -183.81% | 0.15x | 2.20x | $-363.62 Million |
Industry Comparison
This section compares Ginkgo Bioworks Holdings's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $187,025,998
- Average return on equity (ROE) among peers: -94.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ginkgo Bioworks Holdings (DNA) | $508.59 Million | -24.20% | 1.20x | $396.32 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $128.24 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $-20.80 Million | 0.00% | 0.00x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $185.59 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $28.20 Million |
| Abivax SA American Depositary Shares (ABVX) | $196.01 Million | -75.37% | 0.67x | $10.03 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.66 Billion |
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more